CYP3A5基因多态性与他克莫司血药浓度的相关性分析

目的 对CYP3A5基因多态性与他克莫司血药浓度的相关性进行分析，探讨其在临床肾移植患者个体化治疗中的应用意义。方法 选择2014年3月~2016年5月间，笔者医院收治的获得明确诊断、符合条件接受同种异体肾移植手术患者115例作为研究对象，对受试者展开CYP3A5基因型检测，而后对不同基因型患者的他克莫司血药浓度/剂量比值、急性排斥反应、不良反应的发生情况进行对比分析。结果 肾移植术后随访3个月，不同基因型者的他克莫司血药浓度/剂量比值差异有统计学意义，表现为*3/*3基因型患者最高（P<0.05）；术后不良反应发生率比较发现，*3/*3基因型患者的发生率高于其他基因型（P<0.05）；不同基因型患者术后急性排斥反应发生率比较，*1/*1型急性排斥反应发生率高于其他基因型（P<0.05）。结论 CYP3A5基因多态性会影响到应用他克莫司血药浓度/剂量比值，不同基因型的不良反应发生率不同，在今后的临床工作中，应对其给予足够的重视。

Correlation Analysis between CYP3A5 Gene Polymorphisms and Tacrolimus Blood Concentration

Objective The relationship between CYP3A5 gene polymorphism and tacrolimus plasma concentration was analyzed to explore its application in individualized treatment of patients with clinical kidney transplantation. Methods A total of 115 patients with allogeneic renal transplantation were enrolled in our hospital from March 2014 to May 2016, and the subjects were followed up for CYP3A5 genotyping. And then the different genotype of tacrolimus plasma concentration/dose ratio, acute rejection, the incidence of adverse reactions were compared. Results After 3 months follow-up, we found that there were significant differences in the plasma/dose ratio of tacrolimus in different genotypes, which showed the highest *3/*3 genotype (P<0.05). Comparison of postoperative adverse reactions, the incidence of *3/*3 genotype was higher than that of other genotypes (P<0.05). Compared with other genotypes, the incidence of acute rejection in *1/*1 patients was higher than that of others(P<0.05). Conclusion The polymorphism of CYP3A5 gene may affect the application of tacrolimus concentration/dose ratio. In different genotypes, the incidence of adverse reactions was different. So, we should be given enough attention in the future clinical work.